EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD)

Suet Ching Chen iD, Angela K Lucas-Herald iD, Ruoning Tang, Xanthippi Tseretopoulou, Malika Alimussina, Deno Andrews, Beverly M K Biller, Cesar L Boguszewski, Jillian Bryce, Minglu Chen, Peter E Clayton, Maria Fleseriu iD und 15 weitere

Clinical Endocrinology · 2025

DOI: 10.1111/cen.15298 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Suet Ching Chen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Human Growth Hormone, Hormone Replacement Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by Chief Scientist Office., Chief Scientist Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify the minimum dataset (MDS) for the monitoring of safety and effectiveness of GH in adults with growth hormone deficiency (AGHD).

Design

Systematic review and expert consensus.

Methods

Outcomes for AGHD were identified through a systematic literature search in PubMed, Science Direct and Cochrane. In addition, 17 clinical experts from 10 countries and two patient representatives assembled through the Global Registry for Novel Therapies in Rare Bone and Endocrine Conditions (GloBE‐Reg) provided data items that ideally should be collected routinely. These items were subsequently graded independently by participants on: (1) importance of the data field and (2) ease of data collection in routine clinical practice.

Results

The systematic review identified 35 studies with 6732 participants with AGHD with a median age of 49 (range, 22–82) years. The common outcome categories included were cardiovascular in 21 (60%) studies, serum IGF‐I in 13 (37%) and IGF‐I SDS in 8 (23%), adiposity measures in 15 (44%) and psychosocial outcomes in 10 (29%). A total of 190 items were provided by experts and 86 (45%) achieved sufficient consensus and alignment with reported outcomes to create a final MDS with 45 items to be assessed, of which only 43 are manually entered.

Conclusions

This study has identified by consensus a minimum dataset considered necessary to provide consistency and comparability in global studies of AGHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneHormone Replacement TherapyHumansAdultMiddle AgedAgedFemaleYoung AdultMaleAged, 80 and overInsulin-Like Growth Factor ITreatment Outcome

Stichwörter der Autor:innen

adultscore outcomeseffectivenessgrowth hormonegrowth hormone deficiencygrowth hormone replacementsafety

Substanzen

Human Growth HormoneInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.
  • Office for Rare Conditions, University of Glasgow, Glasgow, UK.
  • Chicago, Illinois, USA.
  • Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil.
  • University of Manchester, Manchester, UK.

ORCID-Profile: Suet Ching Chen, Angela K Lucas-Herald, Maria Fleseriu, S Faisal Ahmed

Förderung

  • This study was supported by Chief Scientist Office.
  • Chief Scientist Office

Zitieren

APA

Chen, S. C., Lucas-Herald, A. K., Tang, R., Tseretopoulou, X., Alimussina, M., Andrews, D., Biller, B. M. K., Boguszewski, C. L., Bryce, J., Chen, M., Clayton, P. E., Fleseriu, M., Gebauer, J., Ho, K. K. Y., Jorgensen, J. O. L., Luo, X., Miller, B. S., Neggers, S. J., Sävendahl, L., …, & Ahmed, S. F. (2025). Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD). Clinical Endocrinology. https://doi.org/10.1111/cen.15298

Vancouver

Chen SC, Lucas-Herald AK, Tang R, Tseretopoulou X, Alimussina M, Andrews D, et al. Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD). Clinical Endocrinology. 2025. doi:10.1111/cen.15298

BibTeX
@article{Chen2025,
  author = {Chen, Suet Ching and Lucas-Herald, Angela K and Tang, Ruoning and Tseretopoulou, Xanthippi and Alimussina, Malika and Andrews, Deno and Biller, Beverly M K and Boguszewski, Cesar L and Bryce, Jillian and Chen, Minglu and Clayton, Peter E and Fleseriu, Maria and Gebauer, Judith and Ho, Ken K Y and Jorgensen, Jens Otto L and Luo, Xiaoping and Miller, Bradley S and Neggers, Sebastian Jcmm and Sävendahl, Lars and Schilbach, Katharina and Strasburger, Christian J and Takahashi, Yutaka and Vitali, Diana and Yuen, Kevin C J and Hoffman, Andrew R and Johannson, Gudmundur and Ahmed, S Faisal},
  title = {Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD)},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.15298}
}
Kostenlos starten →